Literature DB >> 14725911

Cancer of the larynx in females.

B Sas-Korczynska1, S Korzeniowski, J Skolyszewski.   

Abstract

PURPOSE: The aim of this paper is to present results of analysis of 102 females with laryngeal cancer.
MATERIALS AND METHODS: Between 1974 and 1995, 102 female patients with cancer of larynx were treated at Radiotherapy Department of Oncology Centre in Kraków. Twenty-six of them had positive familial oncological history. The treatment method depended on stage of disease. Primary radical irradiation was performed in 66 patients, 29 patients received postoperative radiotherapy after surgery (total or partial laryngectomy), seven patients received induction chemotherapy followed by laryngectomy with postoperative radiotherapy or radical irradiation. The median dose applied with radiotherapy was 60 Gy, and dose per fraction was 2 Gy.
RESULTS: The actuarial 5-year rates were as follows: 88.9% for overall survival, 84.2% for disease-free survival, and 85.4% for local control. Only tumour stage and nodal involvement were found to be significant factor for all three endpoints. We found that younger patients had more supraglottic primary localisation, and these patients frequently were non-smoker.
CONCLUSIONS: The tumour stage and nodal involvement were found to be significant prognostic factors in analysed group of female treated with laryngeal cancer.

Entities:  

Mesh:

Year:  2003        PMID: 14725911     DOI: 10.1016/j.canrad.2003.07.002

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Primary carcinoma of the larynx in females: A case series.

Authors:  Y Oukessou; A Chebaatha; O Berrada; R L Abada; S Rouadi; M Roubal; M Mahtar; M Regragui; M Karkouri
Journal:  Ann Med Surg (Lond)       Date:  2022-05-25

2.  Investigation of the synergism between alcohol consumption and herpes simplex virus in patients with laryngeal squamous cell cancers.

Authors:  Ozgür Oksüzler; Evrim E Unsal Tuna; Harun Soyaliç; Cem Ozbek; Cafer Ozdem
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-04-03       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.